![Juergen A. Martens](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Juergen A. Martens
Plus aucun poste en cours
Profil
Juergen A.
Martens worked as VP-Pharmaceutical Technology Development at Nektar Therapeutics from 2000 to 2005.
He then worked as Chief Operating Officer at MannKind Corp.
from 2015 to 2016, and as Chief Operations & Technology Officer at Neos Therapeutics, Inc. from 2016 to 2017.
Martens received his undergraduate degree from Mannheim Technical College, and his graduate and doctorate degrees from Philipps University of Marburg.
He also received a graduate degree from the University of Pennsylvania.
Anciens postes connus de Juergen A. Martens
Sociétés | Poste | Fin |
---|---|---|
NEOS THERAPEUTICS, INC. | Directeur des opérations | 30/06/2017 |
MANNKIND CORPORATION | Directeur des opérations | 18/03/2016 |
NEKTAR THERAPEUTICS | Directeur Technique/Scientifique/R&D | 01/08/2005 |
Formation de Juergen A. Martens
University of Pennsylvania | Graduate Degree |
Philipps University of Marburg | Doctorate Degree |
Mannheim Technical College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
NEKTAR THERAPEUTICS | Health Technology |
MANNKIND CORPORATION | Health Technology |
Entreprise privées | 1 |
---|---|
Neos Therapeutics, Inc.
![]() Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |